| Not Yet Recruiting | Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refr Relapsed or Refractory Large B-cell Lymphoma | Phase 3 | 2026-08-01 |
| Not Yet Recruiting | A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis | Phase 1 | 2026-03-01 |
| Enrolling By Invitation | A Study of KITE-363 in Participants With Refractory Autoimmune Diseases Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis | Phase 1 | 2025-07-02 |
| Recruiting | A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-c Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | 2024-09-20 |
| Recruiting | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refract Multiple Myeloma | Phase 3 | 2024-08-23 |
| Active Not Recruiting | Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refr Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Phase 2 | 2024-03-18 |
| Active Not Recruiting | Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma Relapsed/Refractory Large B-cell Lymphoma | Phase 1 | 2023-11-09 |
| Active Not Recruiting | Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants High-risk Large B-cell Lymphoma (LBCL) | Phase 3 | 2023-02-10 |
| Terminated | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt Lymphoma | Phase 2 | 2022-11-01 |
| Active Not Recruiting | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Foll Relapsed/Refractory Follicular Lymphoma | Phase 3 | 2022-09-22 |
| Completed | Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Relapsed or Refractory Large B-cell Lymphoma | Phase 2 | 2022-08-09 |
| Active Not Recruiting | Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) Multiple Myeloma | Phase 2 | 2022-07-15 |
| Enrolling By Invitation | Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Solid and Hematological Malignancies | — | 2021-12-15 |
| Recruiting | Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma Relapsed and/or Refractory B-cell Lymphoma | Phase 1 / Phase 2 | 2021-10-27 |
| Terminated | Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 | 2021-07-19 |
| Completed | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Co Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | 2021-04-27 |
| Terminated | Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymph Relapsed/Refractory Large B-cell Lymphoma | Phase 1 | 2020-05-26 |
| Active Not Recruiting | Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma Relapsed and Refractory Multiple Myeloma | Phase 1 | 2019-12-23 |
| Completed | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory L Refractory Large B-cell Lymphoma | Phase 2 | 2019-11-05 |
| Terminated | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | 2019-10-10 |
| Completed | Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants Wit B-cell Lymphoma | Phase 2 | 2019-01-29 |
| Terminated | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large Relapsed/Refractory Large B-cell Lymphoma | Phase 1 | 2018-11-20 |
| Terminated | Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/R Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma | Phase 1 | 2018-11-15 |
| Completed | Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relaps Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 3 | 2018-01-25 |
| Terminated | Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adu Solid Tumor | Phase 1 | 2017-12-27 |
| Terminated | Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myelom Relapsed/Refractory Multiple Myeloma | Phase 1 | 2017-10-20 |
| Completed | A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 2 | 2017-06-06 |
| Completed | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Lar Refractory Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | 2016-09-29 |
| Completed | A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relap Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2016-03-07 |
| Completed | Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Re Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | 2016-02-01 |
| Completed | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Co Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | 2015-11-09 |
| Completed | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgk Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL) | Phase 1 / Phase 2 | 2015-04-21 |
| Approved For Marketing | Axicabtagene Ciloleucel Expanded Access Study Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma, Relapsed/Refractory Transformed Follicular Lymphoma | — | — |
| Available | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Cilole Large B-cell Lymphoma, Follicular Lymphoma | — | — |
| Available | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Auto Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia | — | — |
| Approved For Marketing | Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Relapse/Refractory Mantle Cell Lymphoma | — | — |